Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Merck KGaA has moved quickly under new CEO Kai Beckmann, agreeing to acquire Bio-Techne (NASDAQ:TECH) in an all-cash transaction valued at roughly $11.3 billion to $11.4 billion.</li><li>The proposed deal, priced at $73 per share, represents a 24% premium to Bio-Techne’s prior closing price and would be Merck’s largest acquisition since its $17 billion purchase of Sigma-Aldrich more than a decade ago.</li><li>The timing is important: Merck has faced flat sales growth in recent years, its shares remain materially below 2022 levels, and Beckmann has already signaled that acquisitions will be a central lever for growth across the group.</li></ul>

Merck KGaA has moved quickly under new CEO Kai Beckmann, agreeing to acquire Bio-Techne (NASDAQ:TECH) in an all-cash transaction valued at roughly $11.3 billion to $11.4 billion.The proposed deal, priced at $73 per share, represents a 24% premium to Bio-Techne’s prior closing price and would be Merck’s largest acquisition since its $17 billion purchase of Sigma-Aldrich more than a decade ago.The timing is important: Merck has faced flat sales growth in recent years, its shares remain materially below 2022 levels, and Beckmann has already signaled that acquisitions will be a central lever for growth across the group.

Merck’s $11 Billion Bio-Techne Bet Could Change Everything!

Merck & Co

Merck’s $11 Billion Bio-Techne Bet Could Change Everything!